Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 402 abstracts

no pagination
Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene. 2000 Dec 11;19(53):6144-51.
Young RC. The sounds of silence. Nature. 2000 Nov 09;408(6809):141.
Zhou T, Guo JT, Nunes FA, Molnar-Kimber KL, Wilson JM, Aldrich CE, Saputelli J, Litwin S, Condreay LD, Seeger C, Mason WS. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J Virol. 2000 Dec;74(24):11754-63.
Bonin SR, Pajak TF, Russell AH, Coia LR, Paris KJ, Flam MS, Sauter ER. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer. 1999 Mar 15;85(6):1226-33.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson A. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). Cancer. 1999 Jan 15;85(2):290-4.
Langer CJ. The role of tegafur/uracil in pulmonary malignancy. Drugs. 1999 Jan;58 Suppl 3:71-5.
Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999 Dec;45(5):1143-9.
Watson JC, Sutanto-Ward E, Osaku M, Weinstein JK, Babb JS, Sigurdson ER. Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats. Surgery. 1999 Aug;126(2):358-63.
Bookman MA. Biological therapy for gynecologic malignancies. Cancer Treat Res. 1998 Jan;95:115-47.
Dresler CM. Kidney metastases. Chest Surg Clin N Am. 1998 Feb;8(1):127-9.
Ozols RF. Chemotherapy of ovarian cancer. Cancer Treat Res. 1998 Jan;95:219-34.
Sokol DB, Hudes GR. Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report. Am J Clin Oncol. 1998 Aug;21(4):420-1.
Fowble B. Postmastectomy radiation: then and now. Oncology (Huntingt). 1997 Feb;11(2):213-34, 239; discussion 239-40, 243.
Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 1997 Feb;15(1):13-9.
Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O'Dwyer PJ. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol. 1997 Feb;15(2):773-80.
Murphy-Boesch J, Li CW, He L, Padavic-Shaller KA, Negendank W, Brown TR. Proton-decoupled 19F spectroscopy of 5-FU catabolites in human liver. Magn Reson Med. 1997 Mar;37(3):321-6.
Weiner LM, Alpaugh RK, von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer immunology, immunotherapy : CII. 1997 Nov;45(3-4):190-2.
Wilkinson Jt, Clapper ML. Detoxication enzymes and chemoprevention. Proc Soc Exp Biol Med. 1997 Nov;216(2):192-200.
O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use Human drug therapy US Gov't Support-PHS Female Non-US Gov't Support administration & dosage Antineoplastic Combined Chemotherapy Protocols Male pathology Neoplasms Antineoplastic Agents Adult Middle Age Aged Clinical Trials metabolism Cisplatin prevention & control radiotherapy Local Neoplasm Recurrence Fluorouracil Combined Modality Therapy Bispecific Antibodies Ovarian Neoplasms immunology therapy Prospective Studies Treatment Outcome Lung Neoplasms Animal Immunotherapy adverse effects pharmacology chemically induced drug effects Survival Rate Squamous Cell Carcinoma Prognosis Non-Small-Cell Lung Carcinoma Time Factors Disease-Free Survival surgery pharmacokinetics Risk Factors secondary US Gov't Support-Non-PHS Passive Immunization Fatigue Fever Radioimmunotherapy Protein p53 Age Factors epidemiology Survival Analysis Enzymes blood Disease Progression Rats Multivariate Analysis toxicity 80 and over Aged Drug Delivery Systems Imaging Phantoms Area Under Curve Spinal Muscular Atrophy Leucovorin Enzyme Induction Breast Neoplasms Meta-Analysis Experimental Liver Neoplasms mortality Immunohistochemistry Carcinogens Agranulocytosis Salvage Therapy dosage Karnofsky Performance Status Metabolic Clearance Rate Prostatic Neoplasms IgG Receptors Growth Substances Sesquiterpenes Paclitaxel Liver genetics Lamivudine Neoplasm Antibodies adverse methods physiopathology Quality-Adjusted Life Years Randomized Controlled Trials Adenocarcinoma Immunoglobulin G Testicular Neoplasms Combination Drug Therapy Antineoplastic Antibiotics Retrospective Studies effects Kidney Neoplasms Neoplasm Drug Resistance Bilirubin Cultured Tumor Cells Drug Combinations Genetic Engineering Stomach Neoplasms Superantigens Chronic Hepatitis B United States Tegafur Interferons instrumentation Case Report Carboplatin Anticarcinogenic Agents Cytokines urine physiology Interferon-alpha Marmota Alanine Transaminase Pathologic Neovascularization Antibodies Magnetic Resonance Spectroscopy Drug Synergism Virus Replication erbB-2 Receptor Hormone-Dependent Neoplasms Drug Metabolic Detoxication Adenoviridae Aspartate Aminotransferases Etoposide Recurrence Neoplasm Staging Vomiting antagonists & inhibitors beta-Alanine Woodchuck Hepatitis B Virus Female Genital Neoplasms Nausea Antitumor Drug Screening Assays World Health Enzyme Inhibitors Antibody-Dependent Cell Cytotoxicity Indoles Estramustine Drug Administration Schedule analogs & derivatives Reverse Transcriptase Inhibitors
Last updated on Friday, July 10, 2020